TY - JOUR
T1 - Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions
T2 - evidence from an international multi-centre study
AU - the ICSN DCIS Working Group
AU - Ponti, Antonio
AU - Ronco, Guglielmo
AU - Lynge, Elsebeth
AU - Tomatis, Mariano
AU - Anttila, Ahti
AU - Ascunce, Nieves
AU - Broeders, Mireille
AU - Bulliard, Jean Luc
AU - Castellano, Isabella
AU - Fitzpatrick, Patricia
AU - Frigerio, Alfonso
AU - Hofvind, Solveig
AU - Májek, Ondřej
AU - Segnan, Nereo
AU - Taplin, Stephen
PY - 2019/10/1
Y1 - 2019/10/1
N2 - PURPOSE: Nuclear grade is an important indicator of the biological behaviour of ductal carcinoma in situ (DCIS). De-escalation of treatment has been suggested for low-grade DCIS. Our aim is to estimate the relative rate of progression of DCIS by nuclear grade by analysing the distribution of nuclear grade by detection at initial or subsequent screening.METHODS: We asked International Cancer Screening Network sites to complete, based on their screening and clinical databases, an aggregated data file on DCIS detection, diagnosis and treatment.RESULTS: Eleven screening programs reported 5068 screen-detected pure DCIS in nearly 7 million screening tests in women 50-69 years of age. For all programs combined, low-grade DCIS were 20.1% (range 11.4-31.8%) of graded DCIS, intermediate grade 31.0% and high grade 48.9%. Detection rates decreased more steeply from initial to subsequent screening in low compared to high-grade DCIS: the ratios of subsequent to initial detection rates were 0.39 for low grade, 0.51 for intermediate grade, and 0.75 for high grade (p < 0.001).CONCLUSIONS: These results suggest that the duration of the preclinical detectable phase is longer for low than for high-grade DCIS. The findings from this large multi-centre, international study emphasize that the management of low-grade DCIS should be carefully scrutinized in order to minimize overtreatment of screen-detected slow-growing or indolent lesions. The high variation by site in the proportion of low grade suggests that further pathology standardization and training would be beneficial.
AB - PURPOSE: Nuclear grade is an important indicator of the biological behaviour of ductal carcinoma in situ (DCIS). De-escalation of treatment has been suggested for low-grade DCIS. Our aim is to estimate the relative rate of progression of DCIS by nuclear grade by analysing the distribution of nuclear grade by detection at initial or subsequent screening.METHODS: We asked International Cancer Screening Network sites to complete, based on their screening and clinical databases, an aggregated data file on DCIS detection, diagnosis and treatment.RESULTS: Eleven screening programs reported 5068 screen-detected pure DCIS in nearly 7 million screening tests in women 50-69 years of age. For all programs combined, low-grade DCIS were 20.1% (range 11.4-31.8%) of graded DCIS, intermediate grade 31.0% and high grade 48.9%. Detection rates decreased more steeply from initial to subsequent screening in low compared to high-grade DCIS: the ratios of subsequent to initial detection rates were 0.39 for low grade, 0.51 for intermediate grade, and 0.75 for high grade (p < 0.001).CONCLUSIONS: These results suggest that the duration of the preclinical detectable phase is longer for low than for high-grade DCIS. The findings from this large multi-centre, international study emphasize that the management of low-grade DCIS should be carefully scrutinized in order to minimize overtreatment of screen-detected slow-growing or indolent lesions. The high variation by site in the proportion of low grade suggests that further pathology standardization and training would be beneficial.
KW - Breast cancer screening
KW - Ductal carcinoma in situ
KW - Low-grade DCIS
KW - Overtreatment
KW - Early Detection of Cancer
KW - Humans
KW - Middle Aged
KW - Carcinoma, Intraductal, Noninfiltrating/diagnosis
KW - Disease Progression
KW - Breast Neoplasms/diagnosis
KW - United States/epidemiology
KW - Mass Screening
KW - Neoplasm Grading
KW - Female
KW - Aged
KW - Neoplasm Staging
UR - http://www.scopus.com/inward/record.url?scp=85068202649&partnerID=8YFLogxK
U2 - 10.1007/s10549-019-05333-6
DO - 10.1007/s10549-019-05333-6
M3 - Article
C2 - 31250357
AN - SCOPUS:85068202649
SN - 0167-6806
VL - 177
SP - 761
EP - 765
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -